ArticleArthritis research & therapy2011
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.
Article in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 72 citations in OpenAlex.
- Big Data May Have Big Pitfalls: Ensuring Rigor in Rheumatic Disease Epidemiology.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi.BMC gastroenterology · 2026Article
- Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Adipokines and Associations With Incident Osteoporotic Fracture in Patients With Rheumatoid Arthritis.Arthritis care & research · 2026Article
- The Veterans Affairs Rheumatoid Arthritis Registry: A unique population in rheumatoid arthritis research.Seminars in arthritis and rheumatism · 2025Review
- Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies.Drug, healthcare and patient safety · 2025Review
- Estimation of optimal adherence threshold for tumor necrosis factor inhibitors in rheumatoid arthritis.Clinical rheumatology · 2024Article
- Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis.Pharmacoepidemiology and drug safety · 2024Article
- Real-World Treatment Effectiveness of Disease-Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis.ACR open rheumatology · 2023Article
- Data Challenges for Externally Controlled Trials: Viewpoint.Journal of medical Internet research · 2023Article
- Risk of Prostate Cancer in US Veterans With Rheumatoid Arthritis.Arthritis care & research · 2023Article
- Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.BMC gastroenterology · 2023Article
- Elevations in adipocytokines and mortality in rheumatoid arthritis.Rheumatology (Oxford, England) · 2022Article
- Adipocytokines and achievement of low disease activity in rheumatoid arthritis.Seminars in arthritis and rheumatism · 2022Article
- Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict.Clinical pharmacology and therapeutics · 2022Review
- Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.Annals of the rheumatic diseases · 2021Article
- Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis.RMD open · 2021Article
- Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.Advances in therapy · 2021Article
- Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.Journal of managed care & specialty pharmacy · 2020Article
- Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.Journal of managed care & specialty pharmacy · 2020Observational
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
introductionAdministrative claims data have not commonly been used to study the clinical effectiveness of medications for rheumatoid arthritis (RA) because of the lack of a validated algorithm for this outcome. We created and tested a claims-based algorithm to serve as a proxy for the clinical effectiveness of RA medications.
methodsWe linked Veterans Health Administration (VHA) medical and pharmacy claims for RA patients participating in the longitudinal Department of Veterans Affairs (VA) RA registry (VARA). Among individuals for whom treatment with a new biologic agent or nonbiologic disease-modifying agent in rheumatic disease (DMARD) was being initiated and with registry follow-up at 1 year, VARA and administrative data were used to create a gold standard for the claims-based effectiveness algorithm. The gold standard outcome was low disease activity (LDA) (Disease Activity Score using 28 joint counts (DAS28) ≤ 3.2) or improvement in DAS28 by > 1.2 units at 12 ± 2 months, with high adherence to therapy. The claims-based effectiveness algorithm incorporated biologic dose escalation or switching, addition of new disease-modifying agents, increase in oral glucocorticoid use and dose as well as parenteral glucocorticoid injections.
resultsAmong 1,397 patients, we identified 305 eligible biologic or DMARD treatment episodes in 269 unique individuals. The patients were primarily men (94%) with a mean (± SD) age of 62 ± 10 years. At 1 year, 27% of treatment episodes achieved the effectiveness gold standard. The performance characteristics of the effectiveness algorithm were as follows: positive predictive value, 76% (95% confidence interval (95% CI) = 71% to 81%); negative predictive value, 90% (95% CI = 88% to 92%); sensitivity, 72% (95% CI = 67% to 77%); and specificity, 91% (95% CI = 89% to 93%).
conclusionsAdministrative claims data may be useful in evaluating the effectiveness of medications for RA. Further validation of this effectiveness algorithm will be useful in assessing its generalizability and performance in other populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.